Compare BIO-TECHNE Corp (TECH) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Vanguard S&P 500 Growth Index Fund ETF trades at $84.94. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals.
| TECH | VOOG | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.29 | $85.42 |
52-Week Low | $43.31 | $65.32 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $85.42, up 0.68% on the day and near a 52-week high. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI suggests overbought conditions. Recent news highlights institutional accumulation, such as Apella Capital increasing its stake by 463.2% in Q2 2026, and positive coverage from financial outlets comparing its low expense ratio and growth focus favorably against peers.
The outlook for VOOG remains positive, driven by exposure to large-cap growth stocks and strong institutional interest. Key risks include high concentration in technology sectors, making it vulnerable to sector-specific downturns, and broader market volatility. Its low expense ratio of 0.07% and historical outperformance present a compelling case for growth-oriented investors, but caution is warranted given elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
